USPTO serial 78059170
FURIN
Reviewed by CopyMark Law Group
Status 601
- Filing date
- Status date
- Registration date
- —
- Examiner
- GOLDEN, JAMES B
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with FURIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Leuven Vlaams-Brabant, BE
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Genetically engineered animal cells for in vitro production for medical or veterinary use of biological active recombinant proteins or genetically engineered derivatives thereof using co-expression of a gene encoding a proprotein or precursor protein and a gene encoding a proprotein convertase, including genetically engineered animals for in vivo production for medical or veterinary use of biologically active recombinant proteins or genetically engineered derivatives thereof using co-expression of a gene encoding a proprotein or precursor protein and a gene encoding a proprotein convertase, test-tube manufacture for medical or veterinary use of biologically active recombinant proteins genetically engineered derivatives thereof from a proprotein or precursor protein using a proprotein convertase, biologically active recombinant proteins or genetically engineered derivatives of plasma proteins such as blood clotting factors and albumin, biological active recombinant proteins or genetically engineered derivatives of brain proteins such as neuropeptides, polypeptide hormones and receptors, biologically active recombinant proteins or genetically engineered derivatives of growth and differentiation factors such as for instance members of the TGF- BETA/BMP superfamily, biologically active recombinant proteins or genetically engineered derivatives of growth factor receptors such as the type I insulin-like growth factor receptor, biologically active recombinant proteins or genetically engineered derivatives of viral proteins from viruses, such as for example HIV, Ebola virus, Marburg virus, influenza virus, biologically active recombinant protein or genetically engineered derivatives of toxins e.g. anthrax toxin, biologically active recombinant proteins or genetically engineered derivatives of a variety of enzymes such as metalloproteinases and proprotein convertases, biologically active recombinant proteins or genetically engineered derivatives of several cell-surface receptors, adhesion molecules, signaling proteins and extracelluar-martix proteins, biologically active recombinant proteins or genetically engineered derivatives of proteins or fragments thereof for production of vaccines, biological active recombinant proteins or genetically engineered derivatives of any natural occurring of artificially designed proprotein or precursor protein which requires the action of a proprotein convertase for cleavage into biologically active components | ACTIVE | — |
| 005 | biological , chemical, and enzyme preparations for medical and veterinary purposes, namely pharmaceutical preparations used in the treatment of mammals with enzyme insufficiency or deficiency; chemical reagents for medical and veterinary use, namely, clinical medical reagents; medical diagnostic reagents; medicines for human and veterinary purposes, namely, pharmaceutical preparations used in the treatment of mammals with enzyme insufficiency or deficiency | ACTIVE | — |
| 042 | Biological research, namely biomedical research, biochemical research, genetic research, animal cell biotechnology research, agricultural research, and viral research; blood bank services; research and development of new pharmaceutical and research products for others; Professional consultancy, namely, technical consultation in the field of biomedical research, biochemical research, genetic research, animal cell biotechnology research, agricultural research and viral research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 30, 2003 | ABN1 | ABANDONMENT - EXPRESS MAILED | — |
| Mar 19, 2003 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 1, 2002 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 21, 2002 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jun 26, 2002 | NPUB | NOTICE OF PUBLICATION | — |
| Apr 18, 2002 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 5, 2002 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 6, 2001 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 20, 2001 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 17, 2001 | DOCK | ASSIGNED TO EXAMINER | — |